Ropes & Gray has advised Novo Nordisk. Novo Nordisk has entered into an asset purchase agreement to acquire three novel obesity drug development programmes from Kallyope....
Novo Nordisk Acquires Three Obesity Drug Development Programmes from Kallyope
Novo Nordisk Enters into an Asset Purchase and License Agreement with Omeros Corporation
Ropes & Gray advised Novo Nordisk on the transaction. Novo Nordisk announced it has entered into an asset purchase and license agreement with Omeros Corporation (Nasdaq:...
Novo Nordisk to Acquire Akero Therapeutics for Up to $5.2 Billion
Ropes & Gray has advised Novo Nordisk, and Kirkland & Ellis has advised Akero Therapeutics. Novo Nordisk has entered into a definitive agreement to acquire Akero...
Novo Nordisk and Replicate Bioscience Enter Strategic Collaboration for RNA-Based Therapies for Metabolic Diseases
Ropes & Gray has advised Novo Nordisk, and Goodwin Procter has advised Replicate Bioscience. Novo Nordisk has entered into a multi-year strategic partnership with Replicate Bioscience...
Novo Nordisk’s $1 Billion License Agreement with Lexicon
Ropes & Gray advised Novo Nordisk on the transaction. Novo Nordisk announced it has entered into an exclusive license agreement with Lexicon Pharmaceuticals (Nasdaq: LXRX) for...
Novo Nordisk’s $2 Billion License Agreement with United Laboratories
Ropes & Gray advised Novo Nordisk on the transaction. Novo Nordisk announced an exclusive license agreement with China-based United Laboratories International Holdings Limited and its wholly-owned...
Novo Nordisk’s License Agreement with IMMvention Therapeutix
Ropes & Gray represented Novo Nordisk in the transaction. IMMvention Therapeutix, Inc., an early-stage biotechnology company focused on discovering and developing human therapeutics, announced a strategic...
Novo Nordisk’s $4.6 Billion Collaboration with Valo Health
Ropes & Gray advised Novo Nordisk on the transaction. Novo Nordisk announced expanding its collaboration with Valo Health, Inc. (Valo) in a deal worth up to...
NanoVation Therapeutics’ Multi-Target Partnership with Novo Nordisk
Ropes & Gray advised Novo Nordisk on the transaction. Novo Nordisk announced a multi-year partnership with NanoVation Therapeutics to develop genetic medicines for rare and cardiometabolic...
Novo Nordisk’s Collaboration with Flagship Pioneering and Metaphone Biotechnologies
Ropes & Gray advised Novo Nordisk on the transaction. Novo Nordisk announced it has entered into a research collaboration agreement with Flagship Pioneering and Metaphone Biotechnologies,...
Mosaic Health Inc. et al. v. Novo Nordisk
King & Spalding successfully defended Novo Nordisk in a federal antitrust suit in New York alleging Novo Nordisk, along with other major insulin manufacturers, conspired to...
Novo Nordisk’s Partnership with Evotec SE to Launch Translational Drug Discovery Accelerator
Sidley Austin LLP represented Novo Nordisk Inc. in the matter. Novo Nordisk (NYSE: NVO) announced its collaboration with Evotec SE (NASDAQ: EVO) to launch LAB eN² (pronounced Lab...